154 related articles for article (PubMed ID: 24900349)
1. Optimization of the First Selective Steroid-11β-hydroxylase (CYP11B1) Inhibitors for the Treatment of Cortisol Dependent Diseases.
Hille UE; Zimmer C; Haupenthal J; Hartmann RW
ACS Med Chem Lett; 2011 Aug; 2(8):559-64. PubMed ID: 24900349
[TBL] [Abstract][Full Text] [Related]
2. First Selective CYP11B1 Inhibitors for the Treatment of Cortisol-Dependent Diseases.
Hille UE; Zimmer C; Vock CA; Hartmann RW
ACS Med Chem Lett; 2011 Jan; 2(1):2-6. PubMed ID: 24900247
[TBL] [Abstract][Full Text] [Related]
3. Discovery of new 7-substituted-4-imidazolylmethyl coumarins and 4'-substituted-2-imidazolyl acetophenones open analogues as potent and selective inhibitors of steroid-11β-hydroxylase.
Stefanachi A; Hanke N; Pisani L; Leonetti F; Nicolotti O; Catto M; Cellamare S; Hartmann RW; Carotti A
Eur J Med Chem; 2015 Jan; 89():106-14. PubMed ID: 25462231
[TBL] [Abstract][Full Text] [Related]
4. Benzophenones as xanthone-open model CYP11B1 inhibitors potentially useful for promoting wound healing.
Gobbi S; Hu Q; Foschi G; Catanzaro E; Belluti F; Rampa A; Fimognari C; Hartmann RW; Bisi A
Bioorg Chem; 2019 May; 86():401-409. PubMed ID: 30769265
[TBL] [Abstract][Full Text] [Related]
5. Cushing's syndrome: development of highly potent and selective CYP11B1 inhibitors of the (pyridylmethyl)pyridine type.
Emmerich J; Hu Q; Hanke N; Hartmann RW
J Med Chem; 2013 Aug; 56(15):6022-32. PubMed ID: 23869452
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase.
Ulmschneider S; Müller-Vieira U; Mitrenga M; Hartmann RW; Oberwinkler-Marchais S; Klein CD; Bureik M; Bernhardt R; Antes I; Lengauer T
J Med Chem; 2005 Mar; 48(6):1796-805. PubMed ID: 15771425
[TBL] [Abstract][Full Text] [Related]
7. Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease.
Emmerich J; van Koppen CJ; Burkhart JL; Hu Q; Siebenbürger L; Boerger C; Scheuer C; Laschke MW; Menger MD; Hartmann RW
J Med Chem; 2017 Jun; 60(12):5086-5098. PubMed ID: 28570067
[TBL] [Abstract][Full Text] [Related]
8. Novel imidazol-1-ylmethyl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-ones as potent and selective CYP11B1 inhibitors for the treatment of Cushing's syndrome.
Yin L; Lucas S; Maurer F; Kazmaier U; Hu Q; Hartmann RW
J Med Chem; 2012 Jul; 55(14):6629-33. PubMed ID: 22788843
[TBL] [Abstract][Full Text] [Related]
9. Identification of 4-(4-nitro-2-phenethoxyphenyl)pyridine as a promising new lead for discovering inhibitors of both human and rat 11β-Hydroxylase.
Hu Q; Kunde J; Hanke N; Hartmann RW
Eur J Med Chem; 2015; 96():139-50. PubMed ID: 25874338
[TBL] [Abstract][Full Text] [Related]
10. Disorganized Steroidogenesis in Adrenocortical Carcinoma, a Case Study.
Uchida T; Nishimoto K; Fukumura Y; Asahina M; Goto H; Kawano Y; Shimizu F; Tsujimura A; Seki T; Mukai K; Kabe Y; Suematsu M; Gomez-Sanchez CE; Yao T; Horie S; Watada H
Endocr Pathol; 2017 Mar; 28(1):27-35. PubMed ID: 27430645
[TBL] [Abstract][Full Text] [Related]
11. Replacement of imidazolyl by pyridyl in biphenylmethylenes results in selective CYP17 and dual CYP17/CYP11B1 inhibitors for the treatment of prostate cancer.
Hu Q; Jagusch C; Hille UE; Haupenthal J; Hartmann RW
J Med Chem; 2010 Aug; 53(15):5749-58. PubMed ID: 20684610
[TBL] [Abstract][Full Text] [Related]
12. Accelerated skin wound healing by selective 11β-Hydroxylase (CYP11B1) inhibitors.
Emmerich J; van Koppen CJ; Burkhart JL; Engeli RT; Hu Q; Odermatt A; Hartmann RW
Eur J Med Chem; 2018 Jan; 143():591-597. PubMed ID: 29207342
[TBL] [Abstract][Full Text] [Related]
13. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension.
Bureik M; Hübel K; Dragan CA; Scher J; Becker H; Lenz N; Bernhardt R
Mol Cell Endocrinol; 2004 Mar; 217(1-2):249-54. PubMed ID: 15134825
[TBL] [Abstract][Full Text] [Related]
14. 1-Phenylsulfinyl-3-(pyridin-3-yl)naphthalen-2-ols: a new class of potent and selective aldosterone synthase inhibitors.
Grombein CM; Hu Q; Heim R; Rau S; Zimmer C; Hartmann RW
Eur J Med Chem; 2015 Jan; 89():597-605. PubMed ID: 25462268
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore Modeling and
Akram M; Waratchareeyakul W; Haupenthal J; Hartmann RW; Schuster D
Front Chem; 2017; 5():104. PubMed ID: 29312923
[TBL] [Abstract][Full Text] [Related]
16. Structure of human cortisol-producing cytochrome P450 11B1 bound to the breast cancer drug fadrozole provides insights for drug design.
Brixius-Anderko S; Scott EE
J Biol Chem; 2019 Jan; 294(2):453-460. PubMed ID: 30425102
[TBL] [Abstract][Full Text] [Related]
17. Design, Synthesis, and Biological Evaluations of Pyridyl 4,5,6,7-Tetrahydro-4,7-Methanobenzo[
Yin L; Pan Y; Xue Y; Chen X; You T; Huang J; Xu Q; Hu Q
J Med Chem; 2022 Sep; 65(17):11876-11888. PubMed ID: 35975976
[TBL] [Abstract][Full Text] [Related]
18. Discovery and in Vivo Evaluation of Potent Dual CYP11B2 (Aldosterone Synthase) and CYP11B1 Inhibitors.
Meredith EL; Ksander G; Monovich LG; Papillon JP; Liu Q; Miranda K; Morris P; Rao C; Burgis R; Capparelli M; Hu QY; Singh A; Rigel DF; Jeng AY; Beil M; Fu F; Hu CW; LaSala D
ACS Med Chem Lett; 2013 Dec; 4(12):1203-7. PubMed ID: 24900631
[TBL] [Abstract][Full Text] [Related]
19. N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).
Zimmer C; Hafner M; Zender M; Ammann D; Hartmann RW; Vock CA
Bioorg Med Chem Lett; 2011 Jan; 21(1):186-90. PubMed ID: 21129965
[TBL] [Abstract][Full Text] [Related]
20. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis.
Voets M; Antes I; Scherer C; Müller-Vieira U; Biemel K; Barassin C; Marchais-Oberwinkler S; Hartmann RW
J Med Chem; 2005 Oct; 48(21):6632-42. PubMed ID: 16220979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
